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ABSTRACT: Acetylation of histone lysine residues is one of
the most well-studied post-translational modiﬁcations of
chromatin, selectively recognized by bromodomain “reader”
modules. Inhibitors of the bromodomain and extra terminal
domain (BET) family of bromodomains have shown profound
anticancer and anti-inﬂammatory properties, generating much
interest in targeting other bromodomain-containing proteins
for disease treatment. Herein, we report the discovery of I-
BRD9, the ﬁrst selective cellular chemical probe for
bromodomain-containing protein 9 (BRD9). I-BRD9 was
identiﬁed through structure-based design, leading to greater
than 700-fold selectivity over the BET family and 200-fold over
the highly homologous bromodomain-containing protein 7 (BRD7). I-BRD9 was used to identify genes regulated by BRD9 in
Kasumi-1 cells involved in oncology and immune response pathways and to the best of our knowledge, represents the ﬁrst
selective tool compound available to elucidate the cellular phenotype of BRD9 bromodomain inhibition.
■ INTRODUCTION
Chromatin has a highly complex structure composed of
nucleosomes, the fundamental packaging elements of genetic
information. These structural subunits consist of DNA wrapped
around an octameric core of histones, which facilitate the
arrangement of DNA in the nucleus of the cell.1 Histone tails are
subject to a range of post-translational modiﬁcations, aiding the
regulation of chromatin accessibility.2 Acetylation of lysine
residues is an example of one such modiﬁcation and is regulated
by the dynamic action of histone acetyltransferases (HATs) and
histone deacetylases (HDACs), which “write” and “erase”
acetylation marks respectively.3 Bromodomain “reader”modules
recognize speciﬁc acetyl-lysine (Kac) residues located on histone
tails and other proteins. These recognition motifs act together
with other chromatin factors to modulate regulation of gene
transcription.4 Bromodomains are highly conserved protein
modules, comprising approximately 110 amino acids. The
majority are characterized by four alpha-helices, linked by two
ﬂexible loop regions, which form the basis of the Kac binding
pocket.5
There are at least 56 human bromodomains in 42
bromodomain containing proteins (BCPs) identiﬁed to date,
neglecting splice variants, each of which has been classiﬁed into a
distinct subgroup based on sequence homology.6−8 The
bromodomain and extra terminal domain (BET) family of
BCPs (BRD2, BRD3, BRD4, and BRDT) contain two
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bromodomains each, both capable of binding to Kac.3 The most
potent and selective bromodomain inhibitors reported to date
target all eight bromodomains of the BET family.4,9,10 Examples
include I-BET762 (1),11−13 (+)-JQ1 (2),14,15 I-BET151
(3),16−18 I-BET726 (4),19 PFI-1 (5),20 and OXF BD 02
(6)21,22 (Figure 1). There are also examples of compounds
biased toward binding at either the N-terminal bromodomain
(BD1) or C-terminal bromodomain (BD2) of the BET family
such as MS436 (7)23 and RVX-208 (8).24,25
The profound biology associated with the BET family of BCPs
suggests there may be therapeutic potential in targeting other
members of the bromodomain phylogenetic tree for the
treatment of disease. Protein knock-down studies, which block
the action of an entire complex, oﬀer a method for probing
protein function and linking a BCP to a disease.3 However, as
BCPs are multidomain proteins and often exist as part of
multibody complexes, a chemical probe, which only inhibits the
action of the bromodomain, may show diﬀerent eﬀects.26 The
therapeutic potential of bromodomain inhibition remains less
Figure 1. Chemical structures for selected bromodomain inhibitors.
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well explored outside of the BET family,3 in part, due to the
limited availability of suitable chemical probes for each member
of the human bromodomain phylogenetic tree.27 Therefore, the
development of high quality, selective small molecule probes for
bromodomains will be a key step in facilitating validation of these
reader modules as therapeutic targets. Toward this goal, several
groups have generated high quality non-BET bromodomain
inhibitors from a diverse set of chemotypes: PFI-3 (9)28 for
SMARCA2/4 and PB1(5) domains; I-CBP112 (10),29 SGC-
CBP300 (11),30,31 and ischemin (12)32 for CREBBP and
EP300;33 GSK2801 (13)34 for BAZ2B/A, and compound 14 for
BRPF1 (Figure 1).35 NMR-based screening has been used to
identify fragment-sized small molecule inhibitors of PCAF,
BAZ2B, and ATAD2 providing further evidence for the
tractability of non-BET bromodomains.36−38 Additionally, a
ﬂuorous-tagged multicomponent reaction biased around the 3,5-
dimethylisoxazole Kac motif was used to generate the ﬁrst
compounds capable of binding to TAF1.39 There are also several
probes available from the Structural Genomics Consortium for
the following bromodomains that have not yet had their
structures disclosed: BAZ2B/A, BRPF1/2/3, and BRPF1.40
Although BRD9 has been reported as a component of the
chromatin remodeling SWI/SNF BAF complex,41−43 further
information regarding its role within disease is somewhat
limited.44 As such, a chemical probe for the BRD9 bromodomain
would be invaluable in better understanding the biological role
and therapeutic potential of this reader module. The Structural
Genomics Consortium have disclosed bromosporine (15),45 a
broad spectrum bromodomain inhibitor, which shows a thermal
shift of +3.9 °C at BRD9, suggesting bromodomain binding. In
addition, structurally similar compound 16 was reported as the
ﬁrst nonselective inhibitor of BRD9.46,47 This compound shows
mixed bromodomain pharmacology, with submicromolar
activity against BRD9, BRD4, CECR2, and CREBBP. To the
best of our knowledge, there are no BRD9 selective chemical
probes described in the literature to date.48 Herein, we report the
discovery of I-BRD9, the ﬁrst selective cellular chemical probe for
BRD9. The development of I-BRD9 was driven by iterative
medicinal chemistry, utilizing structure based design to deliver
nanomolar potency at BRD9, >700-fold selectivity over the BET
family and >70-fold against a panel of 34 bromodomains. I-BRD9
meets and exceeds the chemical probe criteria we deﬁned at the
outset of this project, inspired by literature from Bunnage and co-
workers,49 who highlighted the importance of high quality
chemical probes for target validation: 100 nM or greater potency
against the bromodomain of BRD9 as determined by a
biochemical assay; 100-fold selectivity over the BET family of
bromodomains; 30-fold selectivity over other bromodomain
families; cellular activity; and broader selectivity over a range of
receptor sites, ion channels, transporters, and enzymes.
■ RESULTS AND DISCUSSION
Throughout the course of the investigations to identify a
chemical probe for BRD9, selectivity over the BET family of
bromodomains was considered of utmost importance. It was felt
that the profound biology associated with BET bromodomain
inhibition9−12 required at least 100-fold selectivity (as
determined using TR-FRET analysis, see Supporting Informa-
tion), to ensure that any phenotype observed through the use of a
BRD9 chemical probe was driven by BRD9 inhibition alone.
BRD4 BD1 (N-terminal, bromodomain 1) was used as a
representative member of the BET family, driving investigations
into selectivity. Analysis of the X-ray crystal structures of apo
BRD9 and BRD4 BD1 in complex with I-BET762 (1) revealed a
distinct contrast in the architecture of their ZA channels, due to
diﬀerences in their constituent amino acids. In BRD9, the
Tyr106 gate keeper residue blocks access to the lipophilic “WPF”
shelf, providing a key diﬀerence to the Ile146 gate keeper residue
present at the equivalent position of BRD4 BD1 (Figure 2, Table
1). At this stage, it was unclear whether or not selectivity could be
gained over the highly homologous BRD7, given its proximity to
BRD9 on the phylogenetic tree and sequence similarity within
the Kac binding pocket (Figure 3, Table 1).50,51
Nonetheless, in order to identify inhibitors of the BRD9
bromodomain, a cross-screening strategy of GSK internal
compounds was conducted. Thienopyridone 17 was identiﬁed
from this eﬀort as a potent binder to BRD9 (TR-FRET assay),
with pIC50 values of 6.7 and 4.7 against BRD9 and BRD4 BD1,
respectively (Figure 4).52
To explain the BRD9 potency of 17 and its selectivity over
BRD4, 1.3 and 1.2 Å resolution X-ray crystal structures were
solved in BRD9 and BRD4 BD1, respectively. The interactions of
the thienopyridone ring are similar in both bromodomains
(Figure 4B−D). In BRD9, the carbonyl moiety of the pyridone
ring forms a direct hydrogen-bond to the side chain NH2 group
of Asn100, the conserved asparagine residue important for Kac
recognition. The pyridone carbonyl also makes a shorter
hydrogen-bond to a conserved water molecule bound by
Tyr57. The pyridone N-methyl group sits in a small cavity
surrounded by four crystallographically conserved water
molecules, Phe45 and Val49. The N-methyl pyridone moiety
acts as a direct structural analogue of Kac (Figure 4D), whose
interactions with BRD9 and BRD4 are typical of those reported
for fragments in the corresponding site of BRD4.50,51 The
thienopyridone rings ﬁll a tight hydrophobic groove formed by
Val49 and Ala54 of the ZA loop on one side, and Tyr106 (the
gatekeeper residue) on the other. The 7-dimethoxyphenyl
substituent extends outward through the ZA channel, in close
Figure 2. X-ray crystal structures of (A) BRD4 BD1 bromodomain
(orange) with I-BET762 (1) (cyan); (B) BRD9 bromodomain (blue);
(C) BRD4 BD1 surface, and (D) BRD9 surface. In each, the conserved
asparagine residue is colored green (BRD4 Asn140/BRD9 Asn100),
and the gatekeeper residue is colored blue (BRD4 Ile146/BRD9
Tyr106). BRD4 Leu94 and BRD9 Ala54 are colored red.
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contact with Phe44 and Ile53 on either face. The dimethoxy
groups participate in a network of hydrogen-bonded water
molecules, the 4-methoxy in particular, in a water-mediated
interaction with the carbonyl of His42.
At the other end of the molecule, the piperazine amide
presents a complex pattern of both desirable and undesirable
interactions (Figure 4E). The ﬁrst unfavorable interaction
involves the amide carbonyl oxygen of the linker, which lies 2.7
Å from the carbonyl oxygen of Ile53, a close interaction for two
electronegative atoms. The second involves the piperidinyl 2-
methylene group, which lies 2.9 Å from the carbonyl oxygen of
the conserved asparagine (Asn100) side chain, preventing its
solvation by water. In compensation, the piperazine amide acts as
Table 1. Sequence Similarity between the Residues of the
Acetyl-Lysine Binding Sites of BRD4 BD1, BRD9, and BRD7a
aColors represent residue properties: dark green = aromatic, light
green = hydrophobic, red = acidic, blue = basic, orange = polar, purple
= proline, white = small. INS = indel.
Figure 3. Bromodomain phylogenetic tree.
Figure 4. (A) pIC50 values for compound 17 in the bromodomains of
BRD9 and BRD4 BD1 as determined by TR-FRET assays.52 (B)
Diﬀerences between X-ray crystal structures of 17 in complex with the
bromodomain of BRD9 (green) and BRD4 BD1 (blue). (C) Binding
mode of 17 in BRD9. Hydrogen-bonds are shown as gray dashed lines
and the four conserved water molecules as red spheres. Unfavorable
interactions are marked as yellow dashed lines. (D) Binding mode of 17
in BRD4 BD1 (blue) with the position of acetyl-lysine (orange,
bromodomains superimposed, from protein data bank entry 2wp2).53
(E,F) Two diﬀerent orientations of the complex of 17 with BRD9.
(G,H) The complex of 17 with BRD4 BD1.
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a conformationally restricted linker, directing the terminal
methyl sulfonamide to a position where one of its oxygen
atoms accepts a hydrogen bond from the backbone NH of
Arg101.
The general binding mode of the thienopyridone to BRD4 is
the same as to BRD9, but more detailed interactions of this
selective compound diﬀer. One diﬀerence arises from the double
substitution of BRD9 Ala54/Tyr106 for BRD4 Leu94/Ile46 on
either side of the thienopyridone ring, leading to a diﬀerently
shaped pocket illustrated in Figure 2. These result in a tilt of the
plane of the thienopyridone ring by approximately 10° away from
Leu94 in BRD4 (Figure 4B). The close proximity of Leu94 in
BRD4 also forces the thiophene 2-position carbonyl bond
torsion into an almost completely planar conformation, in
contrast to the ∼30° angle seen in BRD9. For a model
thienopyridone with a dimethyl amide substituent, the planar
BRD4-bound conformation is calculated to be slightly
unfavorable (∼0.7 kcal/mol) with respect to the energy
minimum, which corresponds to the BRD9-bound conforma-
tion, being ∼30° out-of-plane (see Supporting Information,
Figure S4). Another consequence is a knock-on eﬀect on the
pendant piperidinyl sulfonamide, which must adopt a diﬀerent
position, and as a result the sulfonamide is unable to hydrogen-
bond to the backbone of Lys141 (the equivalent of Arg101 in
BRD9). The electron density for this group is not well-deﬁned
(Figure S2, Supporting Information), but the best placement of
the sulfonamide group is in a region predicted to be
electrostatically unfavorable, close to the side chain oxygen of
Tyr139. We believe that this is consistent with the lower potency
of 17 for BRD4 compared to BRD9. The hydrogen-bonding
potential of Lys141 is satisﬁed not by the sulfonamide but instead
by a water molecule, which also interacts with the side chains of
Asp144 and Asp140 (Figure 4G,H).
With compound 17 as an encouraging hit, key learnings from
the crystallography were taken forward to guide the design of
compounds with greater potency and improved selectivity over
BRD4. With the hypothesis that the selectivity over BRD4 was
driven by the amide carbonyl of compound 17, amide
modiﬁcations were explored to test our idea.
A synthetic route was developed to access the amide analogues
from known bromothienopyridone 1854 (Scheme 1). Halogen-
lithium exchange of bromide 18 with n-BuLi at−78 °C, followed
by the addition of DMF aﬀorded aldehyde 19. Subsequent
electrophilic substitution with NBS, followed by pyridone N-
methylation provided key intermediate 21. Amides 17 and 27−
29 were synthesized by an initial Pinnick oxidation of aldehyde
21 to give acid 22, followed by amide formation. A subsequent
Suzuki−Miyaura coupling with compounds 23−26 was utilized
to install the dimethoxyphenyl motif. In contrast, amide 32 was
synthesized ﬁrst by a Suzuki−Miyaura coupling of intermediate
21, followed by a Pinnick oxidation to aﬀord acid 31. Final amide
formation using standard peptide coupling conditions furnished
compound 32. This alternative route proved more useful,
providing access to late stage intermediate 31. Functionalization
at the 2-position of 31, through a single amide coupling, allowed
for the introduction of structural diversity in the ﬁnal step of the
synthesis, providing straightforward access to a range of amides.
Scheme 1. Synthesis of Amides 17, 27−29, and 32a
aReagents and conditions: (a) n-BuLi, THF, −78 °C, then DMF, THF, −60 °C to rt, 65%; (b) NBS, THF, rt, 79%; (c) MeI, Cs2CO3, THF, rt, 71%;
(d) NaClO2, NaH2PO4, H2O2, DMSO, H2O, rt, 42−72%; (e) HATU, amine, DIPEA, DMF, rt, 13−79%; (f) (3,4-dimethoxyphenyl)boronic acid,
PdCl2(PPh3)2, K2CO3, DME, H2O, microwave, 120 °C, 24−62%.
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Analysis of the resulting data relative to compound 17
indicated that the methyl sulfonamide moiety was important for
BRD9 potency and, as a result, selectivity over BRD4 BD1
(Table 2). Consistent with the hydrogen-bonding interaction
made by the sulfonamide with Arg101 in BRD9 but not Lys141
in BRD4, truncating to piperidine 27 or dimethyl amide 28
reduced BRD9 potency, with little eﬀect on BRD4 activity
(compare compounds 17 to 27 and 28). Interestingly, although
not selective over BRD4, secondary methyl amide 29 regained
the BRD9 potency observed for 17, suggesting that the amide
NH makes positive interactions in both BRD4 and BRD9.
Finally, cyclic sulfone amide 32 provided a 10-fold improvement
in BRD9 activity relative to 29, albeit with little selectivity over
BRD4. X-ray crystallography of 32 in the bromodomains of both
BRD9 and BRD4 was used to rationalize the observed data
(Figure 5).
The binding mode of the thienopyridone ring of 32
superimposes closely with that seen for 17, making identical
interactions (Figure 5A). However, the secondary amide of 32
can move closer to the side chain of Asn100 than is possible for
the tertiary amine of 17, forming a direct hydrogen-bond to the
asparagine side chain carbonyl group. This additional interaction
may explain the increased potency of 29 relative to 28 and
contributes to the greater potency of 32. The electron density for
the tetrahydro-2H-thiopyran 1,1-dioxide substituent is quite
weak, but interestingly the best ﬁt is with the amide at the axial
rather than the equatorial position of the ring (Supporting
Information, Figure S3). Another unexpected feature is that
when complexed to 32 the ZA loop moves away from the
inhibitor compared to its position in the complex with 17 (Figure
5A). This hinge-like motion, involving residues 50−56, results
from the tetrahydro-2H-thiopyran ring pushing on the loop
through its contacts with Tyr99.
Unexpectedly, the selectivity window for BRD9 over BRD4 is
much reduced for 32 than for 17. This can be rationalized by the
crystal structures of the compound bound to the two
bromodomains (Figure 5B). In contrast to the situation for 17
described above, where diﬀerent thiophene-amide bond torsion
angles in each bromodomain give rise to a selectivity window, the
Table 2. SAR for BRD9 and BRD4 BD1 Activity of the Thienopyridone Amide Seriesa
aAll results are n ≥ 3 as determined by TR-FRET analysis.
Figure 5. (A) X-ray crystal structures of BRD9 with 32 (orange) and 17
(green). (B) X-ray crystal structure of 32 in the bromodomains of BRD9
(orange) and BRD4 BD1 (blue). Hydrogen bonds are shown as gray
dashed lines and water molecules as red spheres.
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thiophene and amide of 32 are coplanar when bound to either
bromodomain. As a result, the sulfone of 32 is able to form a
hydrogen bond in each case, to the corresponding backbone NH
atoms of Arg101 in BRD9 and Lys141 in BRD4. The similar
geometry and interactions in each bromodomain account for the
relatively small selectivity window between BRD9 and BRD4.
Despite the low selectivity of 32, the BRD9 potency
encouraged further eﬀort to widen the selectivity window. One
approach suggested by the X-ray crystal structure of 32 in
complex with the bromodomain of BRD9 arose from the
observation that the amide carbonyl lies close (within 5 Å) to the
backbone carbonyl group of Ile53 (Figure 5A). Although the
vectors appeared challenging, it was hypothesized that the
replacement of the amide carbonyl group with a hydrogen-bond
donor moiety, such as an amidine, could increase activity, either
through a direct interaction with the carbonyl of Ile53 or via a
through-water hydrogen-bond. Furthermore, it was postulated
that selectivity could be gained through exploitation of a key
residue diﬀerence between BRD9 and BRD4 BD1. Considering
the basic nature of the amidinemoiety, it was proposed that when
charged it would sit more favorably in the less hydrophobic
environment alongside Ala54 of BRD9 than beside Leu94 of
BRD4 BD1 (Figure 5B). To this end, the amidine analogues of
secondary amides 29 and 32 were designed and accessed
(Scheme 2).
N-Methylation of known thienopyridone 1854 aﬀorded
intermediate 33. Following this, a palladium catalyzed Negishi
cyanation gave nitrile 34. Subsequent bromination at the 7-
Scheme 2. Synthesis of Amidines 38−44a
aReagents and conditions: (a) MeI, Cs2CO3, THF, rt, quant.; (b) Zn(CN)2, Pd(PPh3)4, DMF, microwave, 115 °C, 68%; (c) NBS, THF, rt, 86%; (d)
NaOMe, MeOH, 75 °C, then amine hydrochloride salt, 87%−quant.; (e) R2B(OH)2, K2CO3, PEPPSI-iPr, IPA, H2O, microwave, 120 °C, 4−52%.
Table 3. SAR for BRD9 and BRD4 BD1 Activity of Thienopyridone Amidines and Their Amide Analoguesa
aAll results are n ≥ 3 as determined by TR-FRET.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.5b00256
J. Med. Chem. 2016, 59, 1425−1439
1431
position of the thienopyridone core with NBS provided 35.
Conversion of the nitrile moiety to substituted amidines 36 and
37 was achieved via a Pinner reaction, using NaOMe in MeOH,
followed by addition of the appropriate amine.55 With these key
intermediates in hand, a Suzuki−Miyaura coupling was utilized
to install the diﬀerent aryl motifs, employing the appropriate
boronic acid.
Pleasingly, amidines 38 and 39 retained the BRD9 activity of
their direct amide analogues 29 and 32, respectively, with
improved levels of selectivity over BRD4 BD1 (Table 3).
Transformation of methyl amide 29 to amidine 38 produced a
substantial increase in selectivity from 2 to 16-fold. In addition,
amidine 39was 50-fold selective over BRD4, an improvement on
the four-fold seen for its amide analogue, 32.
These exciting results provided conﬁdence in our hypothesis
that the charged amidine was favored in the less hydrophobic
environment of BRD9. With this in mind, further work was
conducted in order to gain additional selectivity. The 7-position
of the thienopyridone core was selected as an appropriate vector
for modiﬁcation, given its location in the ZA channel. Reaction of
advanced intermediate 37 with various boronic acids provided 7-
aryl substituted compounds containing both electron-donating
and electron-withdrawing substituents (Scheme 2).
Gratifyingly, all amidines (39−44) delivered ≥40-fold
selectivity over the ﬁrst bromodomain of BRD4 (Table 4).
These data indicated that both the amidine and phenyl moieties
were important for selectivity, with the electronics of the phenyl
ring substituents perhaps also playing a role. Unfunctionalized
phenyl substituted compound 40 and other electron-donating
substituents such as 41 and 42 delivered no signiﬁcant
improvement in selectivity over BRD4 BD1 compared to
dimethoxyphenyl derivative 39. However, greater selectivity
resulted from replacement of the electron-donating group by
electron-withdrawing substituents. Nitrile substituted com-
pound 43 delivered a 60-fold selectivity window, while the
triﬂuoromethyl group of compound 44 provided a 160-fold
window, satisfying the BET selectivity56 and BRD9 potency
probe criteria we deﬁned at the outset of this project.
X-ray crystal structures of 44 in the bromodomains of BRD9
and BRD4 BD1 provided insights into the interactions
responsible for the observed selectivity and supported our
hypothesis that led to the synthesis of the amidine. Figure 6A
shows the binding mode in BRD9 of 44 compared to that of 32.
Altering the substituents of the ZA-channel phenyl ring from 3,4-
dimethoxy to 3-triﬂuoromethyl makes essentially no diﬀerence
to the observed binding mode of the core of the molecule. The
subtle change of the amide of 32 to the amidine of 44 maintains
its hydrogen-bond to the conserved Asn100 side chain (Figure
6A) but leads to more notable changes that suggest signiﬁcant
electrostatic diﬀerences between the two molecules. The
stronger electrostatics of the amidine NH group allow it to
move closer to the backbone carbonyl of Ile53 than was possible
with the carbonyl of the amide, resulting in a direct hydrogen-
bond between these groups as we had hoped (Figure 6A). One
result of this is a ∼30° rotation of the thiophene−amidine bond
of 44. This allows the tetrahydro-2H-thiopyran 1,1-dioxide
Table 4. SAR for BRD9 and BRD4 BD1 Activity of Thienopyridone Amidinesa
aAll results are n ≥ 3 as determined by TR-FRET.
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amide substituent to resume its equatorial geometry while
maintaining the hydrogen bond between the cyclic sulfone
oxygen and the backbone NH of Arg101. The combined eﬀect
allows both Tyr99 and residues 50−56 of the ZA loop to relax to
a position similar to that seen in the complex with 17, rather than
the conformation seen with 32.
In contrast, the binding mode of 44 in BRD4 BD1 diﬀers little
from that of 32, with nomovement of the ZA loop (Figure 6B). A
very slight movement of the amidine closer to Asn140 probably
reﬂects a tighter charged hydrogen-bonding interaction. The best
ﬁt to the density of the tetrahydro-2H-thiopyran 1,1-dioxide
amide substituent has equatorial geometry, but this maintains the
hydrogen bond between cyclic sulfone and the backbone NH of
Lys141 (Figure S2, Supporting Information). An explanation for
the reduced BRD4 potency of 44 with respect to 32 is our
original hypothesis that a charged amidine group in close
proximity to the hydrophobic BRD4 Leu94 side chain is
unfavorable (in the X-ray structure, the distance is 3.6 Å). The
basic nature of the amidine functionality was conﬁrmed by
measurement: the pKa of 44 was determined to be 8.4, so the
group would be protonated at neutral pH.
Given the promising activity and selectivity proﬁle displayed
by compound 44, this molecule was taken forward for further
structure−activity relationship (SAR) exploration. It has
previously been reported that Kac mimetics containing alkyl
groups larger than a methyl can be accommodated in the
bromodomain binding pocket.29,57 With this in mind, we sought
to investigate the eﬀect of alternative Kac mimetic alkyl groups.
To this end, N-ethyl analogue 45 and N-isopropyl analogue 46
were synthesized via a similar route to that described in Scheme
2.58
Increasing the Kac mimetic alkyl chain length from N-methyl
to N-ethyl maintained ≥100-fold selectivity over BRD4 BD1
(Table 5). However, the introduction of the more sterically
demanding isopropyl substituent, as in compound 46, reduced
BRD9 and BRD4 activities, suggesting that extending beyondN-
ethyl is not well tolerated in either of these bromodomains
(compare compounds 44 and 46). X-ray crystallography of
compound 45 in complex with BRD9 was obtained in order to
conﬁrm its binding mode. As expected, 45 adopts a similar
conformation to compound 44 (Figure 7A), making identical
interactions to Asn100, Ile53, and Arg101. The N-ethyl Kac
mimetic is comfortably accommodated in the hydrophobic
binding pocket with a slight movement of Phe45, having little
eﬀect on the conformation of the remainder of the site.
In order to assess selectivity over non-BET bromodomains,
compounds 44 and 45were proﬁled in a selection of internal TR-
FRET assays, the results of which indicated that compound 45
displayed a superior selectivity proﬁle. Considering this result,
compound 45 was progressed for BROMOscan59 proﬁling
against 34 bromodomains to evaluate the eﬀect of the N-ethyl
Kac mimetic (Figure 7B). Pleasingly, the results from this
broader bromodomain screen indicated nanomolar aﬃnity
binding at BRD9, with pKd = 8.7 (for full data, see Supporting
Information). Compound 45 showed >700-fold selectivity over
the BET family of bromodomains and 200-fold over the highly
homologous BRD7 bromodomain (pKd = 6.4). Furthermore, 45
displayed >70-fold selectivity against every other bromodomain
tested.
The selectivity of compound 45 over BRD7 is particularly
surprising considering the 85% sequence homology between the
bromodomains of BRD9 and BRD7 (Table 1). Although an
NMR structure of BRD7 has been published,60 there is no crystal
structure reported to date. Therefore, it was challenging to
rationalize the observed selectivity over this bromodomain.
Presumably, selectivity arises from the diﬀerences in the
constituent amino acids of the WPF shelf (BRD4 nomenclature,
see Table 1) and ZA channels of these bromodomains. In BRD9,
Gly43 is replaced by Ala154 in the WPF region of BRD7, and
Ala46, by Ser157 in the ZA channel. These key changes result in a
Figure 6. X-ray structure of (A) 32 (orange) and 44 (green) in BRD9,
showing the rotation around the thiophene−amidine bond of 44. The
signiﬁcant diﬀerence in conformation of the ZA loop that brings the
carbonyl group of Ile53 close to the amidine of 44 is also visible. (B)
Compounds 32 (orange) and 44 (green) in BRD4 BD1 with the 3.6 Å
distance between the amidine nitrogen and Leu94 shown as a yellow
dashed line.
Table 5. SAR for BRD9 and BRD4 BD1 Activity of 3-
Triﬂuoromethylphenyl Substituted Thienopyridone
Amidinesa
Cmpd BRD9 pIC50 BRD4 BD1 pIC50 Fold Selectivity
44 7.8 ± 0.21 5.6 ± 0.03 ×160
45 7.3 ± 0.18 5.3 ± 0.07 ×100
46 5.5 ± 0.26 <4.3 ≥×15
aAll results are n ≥ 3 as determined by TR-FRET analysis.
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diﬀerence in the architecture of these binding regions, potentially
altering the conformation of other residues in the ZA channel.
The observed potency was higher in the BROMOscan format
than in house TR-FRET assays. This may be due to use of the
alternative detection system, protein construct, and sample
preparation methods. As the rank order is maintained between
formats, numerical diﬀerences in the reported aﬃnities did not
aﬀect decision making.
Based on the high BRD9 aﬃnity and excellent broader
bromodomain selectivity results, compound 45 (I-BRD9), was
chosen as the chemical probe for BRD9.
As all measurements of binding aﬃnity of I-BRD9 to date had
been carried out with truncated bromodomain proteins, we were
keen to conﬁrm these ﬁndings were consistent with full-length
targets in their native context. Using a chemoproteomic
competition binding assay in HUT-78 cell lysate, the binding
of I-BRD9 to endogenous BRD9 displayed >625-fold selectivity
against BET family member BRD3 (Figure 8A).58 These data
conﬁrm potency at BRD9, and selectivity over the BET family is
maintained with endogenous proteins.
Critically for a bromodomain probe, cellular target engage-
ment of BRD9 and disruption of chromatin binding was
demonstrated through a NanoBRET assay measuring displace-
ment of NanoLuc-tagged BRD9 bromodomain from Halo-
tagged histone H3.3 (Figure 8B).58
Having established endogenous protein binding, cell and
nuclear permeability, and excellent selectivity over the BET
family and other non-BET bromodomains, further proﬁling of I-
BRD9 was conducted. These experiments aimed to evaluate the
selectivity of the compound over a broad range of pharmaco-
Figure 7. (A) Superimposed X-ray crystal structures of the
bromodomain of BRD9 complexed with compounds 45 (magenta)
and 44 (green), showing the subtle movement of Phe45 in response to
the N1-methyl/ethyl diﬀerence between the two compounds. (B)
BROMOscan data for compound 45 (generated at DiscoveRx Corp.).
Figure 8. (A) Dose−response binding of compound 45 (I-BRD9) for endogenous BRD9 and BRD3 from HuT-78 cell lysates, measured in a
chemoproteomic competition binding assay followed by Western blot analysis. (B) BRD9 bromodomain cellular NanoBRET dose−response curve of
compound 45 (I-BRD9). (C) qPCR validation of CLEC1, DUSP6, FES, and SAMSN1 genes selectively regulated by compound 45 (I-BRD9) (10 μM),
but not by I-BET151 (1 μM), mean ± SD; n = 3. Genes were previously identiﬁed by full gene transcriptomics in Kasumi-1 cells.
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logical targets including various receptors, transporters, ion
channels, kinases, and other enzymes. Pleasingly, I-BRD9
showed no activity at less than 5 μM against a panel of 49
targets.58 A summary of the properties of I-BRD9 is given in
Table 6.
With a high quality soluble and permeable bromodomain
probe in hand, we sought to investigate genes selectively
modulated by BRD9 bromodomain inhibition. Accordingly,
Kasumi-1 cells were treated with I-BET15116−18 and I-BRD9 for
6 h, the concentrations of which were chosen to pharmacolog-
ically match the BET activity of the two probes. RNA was
harvested, reverse transcribed, and hybridized on an Illumina
expression array. While there was an expected overlap, the
majority of genes were selectively regulated by I-BRD9.62
Analysis of four representative genes (CLEC1,63 DUSP6,64
FES,65 and SAMSN166) that were strongly down-regulated by I-
BRD9 and not by I-BET151, by qPCR further validated the
microarray data and gave insights into the eﬀect of BRD9
inhibition (Figure 8C). These four genes are implicated in cancer
and immunology pathways, suggesting for the ﬁrst time a role for
the BRD9 bromodomain in their regulation. This down
regulation also implies potential utility for synergistic disease
modulation by BRD9 inhibition: for example, DUSP6 expression
has been implicated in modulating drug sensitivity in cancers,
which could be important for chemotherapy.64
■ CONCLUSION
Through several iterations of structure-based design, starting
from tertiary amide 17, we have identiﬁed I-BRD9 as the ﬁrst
selective cellular chemical probe for the non-BET bromodomain
BRD9. This key contribution provides for the ﬁrst time the ability
to selectively target BRD9 and further enhances the tool set
available for targeting human bromodomains. Critical to the
success of this endeavor was the selectivity enhancing amidine,
which drove unfavorable interactions between I-BRD9 and the
BET family. This optimized compound is highly potent at BRD9
and displays >700-fold selectivity over the BET family and >70-
fold against the panel of 34 bromodomains tested. It is of note
that I-BRD9 is selective for a single bromodomain, whereas the
vast majority of bromodomain probes bind to ≥2. With proof of
bromodomain cellular target engagement, binding to endoge-
nous BRD9, and broader selectivity against a variety of
pharmacological targets, we believe this molecule satisﬁes the
requirements necessary for a high quality chemical probe. I-
BRD9 was used in the identiﬁcation of a number of BRD9
inhibitor sensitive genes, many of which are involved in immune
function and cancer, which might indicate the biological role of
the BRD9 bromodomain, and provides insight and direction for
further investigation.
■ EXPERIMENTAL SECTION
All solvents were purchased from Sigma-Aldrich (Hy-Dry anhydrous
solvents), and commercially available reagents were used as received. All
reactions were followed by TLC analysis (TLC plates GF254, Merck) or
liquid chromatography mass spectrometry (LCMS) using a Waters ZQ
instrument. IR spectra were obtained on a PerkinElmer Spectrum 1
machine. Melting points were measured with a Stuart SMP10, 230 V
appartus and were uncorrected.
NMR spectra were recorded at ambient temperature using standard
pulse methods on any of the following spectrometers and signal
frequencies: Bruker AV-400 (1H = 400 MHz, 13C = 101 MHz) and
Bruker AV-500 (1H = 500 MHz, 13C = 125 MHz). Chemical shifts are
reported in ppm and are referenced to tetramethylsilane (TMS) or the
following solvent peaks: CDCl3 (
1H = 7.27 ppm, 13C = 77.00 ppm),
DMSO-d6 (
1H = 2.50 ppm, 13C = 39.51 ppm), andMeOH-d4 (
1H = 3.31
ppm, 13C = 49.15 ppm). Coupling constants are quoted to the nearest
0.1 Hz, and multiplicities are given by the following abbreviations and
combinations thereof: s (singlet), d (doublet), t (triplet), q (quartet), m
(multiplet), br (broad). Column chromatography was performed on
prepacked silica gel columns (30−90 mesh, IST) using a biotage SP4.
For detailed LCMS/MDAP/HRMS methodology, see Supplementary
Methods.
The purity of all compounds tested was determined by LCMS and 1H
NMR to be >95%.
Selected Experimental Procedures. 2-Bromo-5-ethylthieno-
[3,2-c]pyridin-4(5H)-one (47). A single portion of ethyl iodide (1.40
mL, 17.39 mmol) was added to a solution of bromothieno[3,2-
c]pyridin-4(5H)-one (18)54 (2.00 g, 8.69 mmol) and Cs2CO3 (8.50 g,
26.10 mmol) in THF (35 mL) at room temperature. The reaction
mixture was heated at 60 °C for 18 h, then allowed to cool to room
temperature and diluted with EtOAc (50 mL) and H2O (50 mL). The
separated aqueous phase was extracted with EtOAc (3 × 50 mL), and
the combined organic layers were passed through a hydrophobic frit and
concentrated in vacuo to give 47 (2.30 g, quant.) as a light brown solid.
Fifty milligrams of 47 was taken forward for puriﬁcation by mass
directed autopreparation (formic acid), providing suitably pure material
(44 mg, 0.17 mmol) for full characterization; mp 124−125 °C; νmax
(solid)/cm−1 1632, 1577, 1082, 846, 761; 1H NMR (500 MHz,
(CD3)2SO) δ ppm 7.62 (s, 1H), 7.56 (d, J = 7.2, 1H), 6.89 (d, J = 7.2,
1H), 3.99 (q, J = 7.2, 2H), 1.24 (t, J = 7.2, 3H); 13C NMR (125 MHz,
(CD3)2SO) δ ppm 156.4, 148.4, 133.8, 130.2, 127.0, 111.7, 100.8, 43.3,
14.6; HRMS (M + H)+ calculated for C9H9BrNOS 257.9583; found
257.9585. LCMS (formic acid) (M + H)+ = 258.0, 260.0, Rt = 0.89 min
(98%).
5-Ethyl-4-oxo-4,5-dihydrothieno[3,2-c]pyridine-2-carbonitrile
(48). A mixture of 47 (1.10 g, 4.26 mmol), zinc cyanide (1.00 g, 8.52
mmol), and Pd(PPh3)4 (0.44 g, 0.3 mmol) in DMF (10 mL) was heated
to 115 °C in a microwave reactor for 3.5 h. This process was repeated to
provide a second identical batch. The two batches were allowed to cool
to room temperature, diluted with EtOAc (50 mL each), and combined.
The solution was ﬁltered through Celite and concentrated in vacuo. The
resulting residue was puriﬁed by silica gel chromatography (0−3%
MeOH in CH2Cl2). The appropriate fractions were combined and
concentrated in vacuo to give 48 (1.70 g, 67%) as a light brown solid.
Fifty milligrams of 48 was taken forward for puriﬁcation by mass
directed autopreparation (formic acid), providing suitably pure material
(33 mg, 0.16 mmol) for full characterization; mp 157−158 °C; νmax
(solid)/cm−1 2211, 1637, 1595, 1247, 1078, 879, 780, 769; 1H NMR
(400 MHz, (CD3)2SO) δ ppm 8.32 (s, 1H), 7.82 (d, J = 7.2, 1H), 7.03
(d, J = 7.2, 1H), 4.00 (q, J = 7.2, 2H), 1.25 (t, J = 7.2, 3H); 13C NMR
(100 MHz, (CD3)2SO) δ ppm 157.1, 151.1, 137.1, 136.7, 128.9, 114.2,
106.4, 100.9, 43.4, 14.5; HRMS (M + H)+ calculated for C10H9N2OS
Table 6. Summary of Properties of I-BRD9
BRD9 pIC50 (TR-FRET) 7.3
BRD4 BD1 pIC50 (TR-FRET) 5.3
BRD9 NanoBRET pIC50 6.8
BROMOscan selectivity over other bromodomains58 BETs: >×700
BRD7: ×200
all others: >×70
ChromLogDpH7.4
61 3.7
aqueous solubility (CLND) 359 μM (high)
artiﬁcial membrane permeability 210 nm/s (high)
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205.0430; found 205.0429. LCMS (formic acid) (M +H)+ = 205.0, Rt =
0.73 min (98%).
7-Bromo-5-ethyl-4-oxo-4,5-dihydrothieno[3,2-c]pyridine-2-car-
bonitrile (49).To a solution of 48 (1.17 g, 5.73 mmol) in THF (20 mL),
NBS (1.53 g, 8.59 mmol) was added portion-wise. The reaction mixture
was left to stir at room temperature for 48 h. The volatile components
were removed in vacuo. The resulting solid was suspended in Et2O (50
mL), ﬁltered under reduced pressure, washed with Et2O (50 mL),
collected, and dried under vacuum at 40 °C to give 49 (1.69 g, quant.) as
an oﬀ-white solid; mp 197−198 °C; νmax (solid)/cm−1 3041, 2220, 1654,
1584, 1250, 1090, 766; 1H NMR (500 MHz, (CD3)2SO) δ ppm 8.50 (s,
1H), 8.26 (s, 1H), 4.02 (q, J = 7.2, 2H), 1.26 (t, J = 7.2, 3H); 13C NMR
(125 MHz, (CD3)2SO) δ ppm 156.1, 152.3, 138.2, 137.6, 128.3, 113.7,
107.0, 90.4, 43.9, 14.4; HRMS (M + H)+ calculated for C10H8BrN2OS
282.9535; found 282.9534. LCMS (formic acid) (M + H)+ = 283.0,
285.0, Rt = 0.93 min (100%).
7-Bromo-N-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-5-ethyl-4-
oxo-4,5-dihydrothieno[3,2-c]pyridine-2-carboximidamide (50). To a
suspension of 49 (1.00 g, 3.53 mmol) in MeOH (30 mL) at room
temperature, sodium methoxide (25% weight in MeOH, 0.81 mL, 3.53
mmol) was added in a single portion. The reactionmixture was heated at
75 °C for 5 h. 4-Aminotetrahydro-2H-thiopyran-1,1-dioxide hydro-
chloride (1.98 g, 10.60 mmol) was added, and the solution was heated
for a further 18 h. The volatile components were removed in vacuo, and
the resulting solid was suspended in Et2O (50 mL), ﬁltered under
reduced pressure, washed with Et2O (50mL), collected, and dried under
vacuum at 40 °C to give 50 (1.55 g, quant.) as a white solid. Fifty
milligrams of 50 was taken forward for puriﬁcation by mass directed
autopreparation (high pH), providing suitably pure material (25 mg,
0.06 mmol) for full characterization; mp 284−285 °C; νmax (solid)/
cm−1 1646, 1578, 1284, 1124, 853, 769; 1H NMR (500 MHz,
(CD3)2SO) δ ppm 8.18 (s, 1H), 8.01 (s, 1H), 6.80 (br.s, 2H), 4.01 (q, J =
7.2, 2H), 3.68−3.61 (m, 1H), 3.27−3.20 (m, 2H), 3.10−3.03 (m, 2H),
2.09−2.00 (m, 2H), 1.99−1.90 (m, 2H), 1.26 (t, J = 7.2, 3H); 13C NMR
(125 MHz, (CD3)2SO) δ ppm 156.9, 149.5, 134.6, 129.7, 123.2, 109.7,
92.0, 48.6, 43.7, 30.2, 14.8; HRMS (M + H)+ calculated for
C15H19BrN3O3S2 432.0046; found 432.0046. LCMS (formic acid) (M
+ H)+ = 432.1, 434.1, Rt = 0.53 min (100%).
N-(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)-5-ethyl-4-oxo-7-(3-
(triﬂuoromethyl)phenyl)-4,5-dihydrothieno[3,2-c]pyridine-2-car-
boximidamide (45, I-BRD9). Amixture of 50 (150 mg, 0.35 mmol), (3-
(triﬂuoromethyl)phenyl)boronic acid (79 mg, 0.42 mmol), PEPPSI-iPr
(21 mg, 0.03 mmol), and K2CO3 (115 mg, 0.83 mmol) in H2O (1 mL)
and IPA (3 mL) was heated at 120 °C in a microwave reactor for 0.5 h.
The reaction mixture was allowed to cool to room temperature, diluted
with EtOAc (40 mL), ﬁltered through Celite, and concentrated in vacuo.
The resulting residue was puriﬁed by mass directed autopreparation
(formic acid). The appropriate fractions were combined and
concentrated in vacuo. The resulting residue was dissolved in MeOH
(5 mL) and passed through a preconditioned (MeOH, 20 mL) amino
propyl column (10 g). The appropriate fractions were combined and
concentrated in vacuo to give 45 (50mg, 29%) as a white solid; mp 228−
229 °C; νmax (solid)/cm
−1 1640, 1587, 1340, 1303, 1117; 1HNMR (500
MHz, (CD3)2SO) δ ppm 8.15 (s, 1H), 8.03−7.98 (m, 1H), 7.98−7.94
(m, 1H), 7.91 (s, 1H), 7.82−7.76 (m, 2H), 6.76 (br.s, 2H), 4.10 (q, J =
7.0, 2H), 3.64−3.57 (m, 1H), 3.21−3.12 (m, 2H), 3.10−3.00 (m, 2H),
2.06−1.96 (m, 2H), 1.96−1.85 (m, 2H), 1.32 (t, J = 7.0, 3H); 13C NMR
(125 MHz, (CD3)2SO) δ ppm 157.6, 149.7, 147.7, 142.2, 137.5, 134.1,
131.9, 130.7, 130.5, 130.3 (q, JC−F = 31.7), 125.0 (q, JC−F = 3.7), 124.60
(q, JC−F = 3.7), 124.59 (q, JC−F = 272.6), 123.1, 114.4, 49.9, 49.0, 44.0,
30.6, 15.2; 19F NMR (376MHz, (CD3)2SO) δ ppm−61.0; HRMS (M+
H)+ calculated for C22H23F3N3O3S2 498.1128; found 498.1110. LCMS
(formic acid) (M + H)+ = 498.1, Rt = 0.81 min (100%).
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■ ABBREVIATIONS USED
BAF, BRG1/brm-associated factor; BAZ2A, bromodomain
adjacent to zinc ﬁnger domain, 2A; BAZ2B, bromodomain
adjacent to zinc ﬁnger domain, 2B; BCP, bromodomain
containing protein; BD, bromodomain; BET, bromodomain
and extra terminal domain; BRD2, bromodomain containing
protein 2; BRD3, bromodomain containing protein 3; BRD4,
bromodomain containing protein 4; BRD7, bromodomain
containing protein 7; BRD9, bromodomain containing protein
9; BRDT, bromodomain containing protein, testis-speciﬁc;
CECR2, cat eye syndrome chromosome region, candidate 2;
CREBBP, cAMP response element-binding protein binding
protein; DIPEA, N,N-diisopropylethylamine; EP300, E1A bind-
ing protein p300; HAT, histone acetyltransferase; HATU, O-(7-
azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexaﬂuor-
ophosphate; HDAC, histone deacetylase; IPA, isopropanol; Kac,
acetyl lysine; LCMS, liquid column mass spectrometry; LPS,
lipopolysaccharide; PB1(5), PolyBromo 1 (5); PCAF, P300/
CREBBP-associated factor; PEPPSI-iPr, pyridine-enhanced
precatalyst preparation stabilization and initiation; PK, pharma-
cokinetics; SMARCA2, SWI/SNF related, matrix associated,
actin dependent regulator of chromatin, subfamily A, member 2;
SMARCA4, SWI/SNF related, matrix associated, actin-depend-
ent regulator of chromatin, subfamily A, member 4; SWI/SNF,
SWItch/sucrose nonfermentable; TR-FRET, time-resolved
Förster (ﬂuorescence) resonance energy transfer
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